What is SMMT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 12.29B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SMMT?

P/E (TTM) is n/a and 52-week range is $12.07 to $29.23 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SMMT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SMMT?

The company profile lists revenue (TTM) near $954K, net income (TTM) near $-8.62B, EPS (TTM) near $-1.12 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Summit Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Miami, Florida, US, 797.8M shares outstanding, ISIN US86627T1088 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Summit Therapeutics Inc

$SMMT

Health Care · Biotechnology

IR Run Scenarios

$15.37

+1.59%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The company is headquartered in Miami, Florida and currently employs 265 full-time employees. The company went IPO on 2004-10-14. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. The company is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Employees

265

Website

www.smmttx.com/

IPO

2004-10-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)